Amanta Healthcare FY26 Earnings Review

Profit Soars, SteriPort Capacity Set to Double

Reader Takeaway: Strong profit growth and SteriPort capacity expansion are key positives, though raw material price volatility presents a challenge.

What Happened

Amanta Healthcare announced its Q4 FY26 financial results, reporting a significant 42% increase in Profit After Tax (PAT) compared to the previous year. The company generated INR288 crore in revenue and INR63 crore in EBITDA, achieving an EBITDA margin of around 22%. A major initiative underway is the substantial expansion of its SteriPort platform, which is expected to more than double its annual bottle production capacity from 6.6 crore to 12 crore units. To boost cost efficiency, Amanta is also installing a 10.8 MW captive solar power project.

Why It Matters

This strong PAT growth signals improved profitability, likely driven by operational efficiencies and the increasing contribution from the SteriPort platform, which now accounts for nearly 42% of the company's revenue. The planned capacity expansion highlights Amanta's focus on future growth, especially within the IV fluid market, which is expanding at an annual rate of 8-10%. Additionally, a stronger balance sheet, with the debt-to-equity ratio improving from 3x to 1x, and reduced finance costs will benefit shareholders.

Background

Amanta Healthcare has strategically focused on disciplined execution, enhancing profitability, and driving operational efficiencies. The SteriPort platform, utilizing advanced ISBM technology, has emerged as a critical revenue generator. The company has also prioritized strengthening its financial position and reducing its overall debt.

What's Next

With SteriPort Line 3 scheduled to become operational by June 20, 2026, it is projected to contribute an estimated INR80-85 crore in revenue for FY27. The full financial impact of this and other expansion projects will be realized in FY28. Amanta Healthcare anticipates its overall EBITDA margins will rise to 24%-25% in the coming years, with SteriPort margins reaching 26%-27%. Long-term, the company expects PAT margins to improve from the current sustainable 5% to over 8%.

Potential Risks

Management noted a considerable increase in plastic raw material prices, rising by 60-70%. To counter this, selling prices have been adjusted, which is expected to add approximately INR2 per bottle for SteriPort products. The company currently holds a four-month buffer of raw materials. The working capital cycle is over 100 days, with a slight expected decrease.

Competitive Landscape

Amanta Healthcare is a key player in the specialized two-port system segment of the IV fluid market. It competes with global companies such as Otsuka and B. Braun. Amanta aims to capture a 20-25% market share in this niche segment by 2030, which is experiencing faster growth than the broader IV fluid market.

Key Metrics to Watch

• FY26 Revenue: INR288 crore
• FY26 EBITDA: INR63 crore (EBITDA Margin: ~22%)
• FY26 PAT Growth: Over 42% Year-on-Year
• SteriPort Contribution: Approximately 42% of FY26 Revenue
• Current IV Fluid Capacity: 6.6 crore bottles/year
• Projected IV Fluid Capacity: 12 crore bottles/year
• Debt-to-Equity Ratio: Improved from 3x to ~1x
• Export Share: 39% of FY26 Revenue
• SteriPort Line 3 Operational Target: June 20, 2026

Next Steps for Investors

Investors should closely track the commissioning of SteriPort Line 3 and the SVP line (expected October-December 2026). Important metrics to monitor include the actual revenue generated by SteriPort, overall EBITDA margins, PAT growth trends, and the progress of the ophthalmic and inhalation product pipeline for commercialization in FY27-28. Reductions in working capital days and finance costs will also be significant indicators.